MDMA patents


1		Owner/Assignee	Patent/Pub. No.	Title	Priority Date	Status	General subject matter
2	1	Institute Of Science And Technology Austria	WO2021074448A1	Stimulation of neuronal plasticity	2019-10-18	Published	Inducing synchronized gamma oscillations by applying a visual stimulus comprising a flashing light, together in some embodiments with an agent including psychedelics and MDMA
3	2	University of Maryland	WO2021030571A1	Methods of Treating Psychological and Brain Disorders	2019-08-12	Published	Methods of treating a psychological disorder by administering a 5-HT agonist in combination with a 5-HT2A antagonist, the 5-HT agonists including MDMA
4	3	Concept Matrix Solutions	US20210015833A1	Oral soft gel capsule containing psychedelic compound	2019-07-18	Pending in US	Softgels containing “psilocybin, psilocin, baeocystin, mescaline, LSD, ketamine, salvinorin A, ibotenic acid, muscimol, DMT, MDMA, MDEA, MDA, & combinations"
5	4	Concept Matrix Solutions	US20210015738A1	Oral dissolvable film containing psychedelic compound	2019-07-17	Pending in US	Films containing “psilocybin, psilocin, baeocystin, mescaline, LSD, ketamine, salvinorin A, ibotenic acid, muscimol, DMT, MDMA, MDEA, MDA, & combinations"
6	5	Karl Dresdner, Michael Cary, Chase Hudson	US20200345585A1	Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness	2019-04-30	Pending in US	Processes for making aqueous therapeutic nanoparticles, including with cannabinoids, psilocybin and related tryptamines, LSD, MDMA and MDA, ayahuasca, and ketamine
7	6	The Regents Of The University Of California	WO2020185581A2	Compositions and methods for modulating lipid and steroid metabolism	2019-03-08	Published	Promoting colonization of spore-forming bacteria in a patient’ s gut, by administering a serotonin receptor agonist, including mescaline, certain subsituted phenethylamines, and MDMA
8	7	Apollo Neuroscience	US20200215297A1	Systems and methods of mitigating negative effects of therapies with transcutaneous vibration	2019-01-04	Pending in US	Transcutaneous vibratory simulation during MDMA-assisted psychotherapy
9	8	Contera Pharma	WO2020127954A1	Treatment of movement disorders	2018-12-20	Published	Pharmaceutical compositions for treating movement disorders comprising a 5-HT1A receptor agonist and an indirect dopamine agonist, including MDMA
10	9	Palo Alto Investors LP	US20200179349A1	Methods of Treating Food Allergy Conditions	2018-12-06	Pending in US	Treating a food allergy, by administration of an empathogen or entactogen, including MDMA
11	10	Douglas Metcalf	WO2020061573A1	Systems and methods to administer pharmaceuticals	2018-09-23	Published	Containers, devices, and methods to administer single doses of drugs by vaporization, including MDMA
12	11	Alpvision	WO2020049182A1	Cognitive computing methods and systems based on biological neural networks	2018-09-08	Published	Cognitive computing systems based on biological neural networks (BNNs), which may comprise additive chemicals that affect the response of the BNN, including MDMA
13	12	Rejoy	US20200060997A1	TARR Receptor Agonists for Sexual Dysfunction	2018-08-27	Pending in US	Topical compositions for female sexual dysfunction, which contract a smooth muscle of the nipple areola complex or increase its sensitivity, comprising trace amine associated receptor agonists, including MDMA
14	13	Applied Biology, Inc.	WO2020023084A1	Taar Receptor Agonists For The Treatment Of Alopecia	2018-07-26	Published	Methods for treating hair shedding by applying a composition of a pilomotor effective amount of a Taar receptor agonist topically, including MDMA
15	14	Leon Rosenberg	WO2020014302A1	Therapeutic combinations for treatment of CNS disorders	2018-07-11	Published	Combination drugs for treating CNS disorders comprising two or more compounds, one of which may be MDMA
16	15	Helium 3 Resources Pty	WO2020006606A1	A pharmaceutical composition and method of use of same	2018-07-05	Published	Combination drugs for treating erectile dysfunction and premature ejaculation comprising penile-erection-inducing agents and orgasm-delaying agents, the orgasm-delaying agents including MDMA
17	16	Robert Petcavich	WO2019246532A1	Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases	2018-06-21	Published	Treating neurodegenerative disease by administration of a psychedelic, including MDMA
18	17	Akili Interactive	WO2019161050A1	Cognitive platform including computerized elements coupled with a therapy for mood disorder	2018-02-18	Published	Computer systems for mood and cognitive assessment during psychedelic-assisted psychotherapy, including with MDMA
19	18	Eleusis	WO2019079742A1	Methods and systems for enhancing safety of psychedelic drug therapies	2017-10-19	Published	Screening a candidate for treatment with psychedelic and empathogenic agents, including MDMA, based on language characteristics from a language sample
20	19	Rhodes Pharmaceuticals	WO2019074829A1	Pharmaceutical resinate compositions and methods of making and using thereof	2017-10-09	Published	Anti-tampering and anti-abuse pharmaceutical compositions comprising an ion exchange resin, a binder, and a matrix material, and methods of making same, to be used with drugs including MDMA
21	20	GW Research	US20200237683A1	Use of cannabidiol in combination with 5-HT2B receptor agonists or amphetamins in the treatment of epilepsy	2017-09-29	Published	Treatments for epilepsy using CBD in combination with a 5-HT2B receptor agonist, amphetamine, or an amphetamine derivative, including MDMA
22	21	Syneurx International Taiwan Corp	US20190151272A1	Lithium salts of N-substituted glycine compounds and uses thereof	2017-07-10	Pending in US	Methods of treating neuropsychiatric disorders, comprising administering a lithium salt of an N-substituted glycine combined in some embodiments with a psychostimulant, including MDMA
23	22	Syneurx International Taiwan Corp	US10226442B2	Lithium salts of N-substituted glycine compounds and uses thereof	2017-07-10	Granted 2019-03-12 (expires 2037-07-10)	Methods of treating neuropsychiatric disorders, comprising administering a lithium salt of N-methylglycine combined in some embodiments with a psychostimulant, including MDMA
24	23	Eleusis	US20200147038A1	Assessing and treating psychedelic-responsive subjects	2017-04-20	Pending in US	Methods of screening a subject for treatment and predicting the subject's responsiveness to treatment with a psychedelic or empathogenic agent, including MDMA
25	24	CaaMTech	US20210085671A1	Compositions and methods comprising a combination of serotonergic drugs	2017-02-09	Pending in US	Combinations of two serotonergic drugs, including psilocybin derivatives, tryptamines, cannabinoids, SSRIs, LSD, and MDMA, and use to treat psychological disorders
26	25	CaaMTech	WO2018148605A1	Compositions and methods comprising a psilocybin derivative	2017-02-09	Published	Methods of modulating activity at a neurotransmitter receptor comprising administering a psilocybin derivative and in some embodiments a serotonergic drug including MDMA
27	26	Insectergy LLC	US10738268B2	Cannabis nanoemulsion methods	2016-08-21	Granted 2020-08-11 (expires 2036-11-01)	Methods to produce cannabis oil nanoemulsions with various compounds including MDMA
28	27	Mamood Valadi	US20180042292A1	Cigarette-like device for administration of substances	2016-08-15	Abandoned	Vaporizer and aerosolizer devices for inhalation of substances including MDMA
29	28	Stanford University	US10641782B2	Methods for visualization and quantification of fiber-like structures	2016-05-25	Granted 2020-05-05 (expires 2037-07-26)	Methods for visualizing fiber-like structures in biological specimens, including where the specimen is from a subject animal exposed to MDMA
30	29	Gruenenthal GmbH	US20170071862A1	Protecting oral overdose with abuse deterrent immediate release formulations	2015-09-10	Pending in US	Dosage forms comprising a drug embedded in a polymer matrix to prevent overdose after accidental or intentional administration of multiple such dosage forms, the drugs including MDMA
31	30	University of South Florida	US10821107	Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use	2015-06-30	Granted 2020-11-03 (expires 2035-06-30)	Methods of treating a neurodegenerative disease or condition, depression, a stress disorder, or an anxiety disorder, with a drug including MDMA, where the patient has one or more FKBP5 gene variants
32	31	Mclean Hospital	US20170312308A11	Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders	2012-12-11	Pending	Methods of treating PTSD and psychiatric disorders using xenon and/or argon, in combination with psychotherapy, and in some embodiments in combination with MDMA
33	32	GlyTech	US10202469B2	Sugar chain-attached linker, compound containing sugar chain-attached linker and physiologically active substance or salt thereof, and method for producing same	2012-11-30	Granted 2019-02-12 (expires 2033-12-11)	Glycosylated drug conjugates (i.e., a glycosylated linker bonded to an active substance) having improved water solubility and release profile, the active substances including MDMA
34	33	SipNose	US10549052B2	Nasal delivery device	2012-02-28	Granted 2020-02-04 (expires 2036-06-13)	Nasal delivery devices using compressed air for intranasal "direct nose-to-brain" administration of drugs including MDMA
35	34	Tokyo Metropolitan Institute of Medical Science	US20170357750A1	Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic amp responsive element binding protein gene	2011-09-30	Abandoned	Methods for evaluating drug sensitivity using genetic polymorphisms, the drugs including MDMA
36	35	Gosforth Centre (Holdings) Pty	US20140142140A1	Pharmaceutical composition for neurological disorders	2011-07-08	Abandoned	Compositions and methods for treating neurological disorders comprising a sub-therapeutic dose of an anti-epileptic agent and a stimulant, including MDMA
37	36	Christian Terreaux et al.	US20130295179A1	Novel omega-3 and omega-6 fatty acid compositions and uses thereof	2010-10-12	Abandoned	Compositions for treating mental disorders and for improving mental health comprising DHA, EPA, and GLA, combined with a psychostimulant, including MDMA
38	37	Emory University	US20120108510A1	Methods of improving behavioral therapies	2010-05-20	Abandoned	Psychedelic-assisted psychotherapy using an oxytocin releasing agent, including MDMA
39	38	Auspex Pharmaceuticals	US20100172916A1	Substituted hydroxyphenylamine compounds	2008-11-10	Abandoned	Method of treating a hormone-mediated disorder or pigment-mediated disorder comprising administration of compounds which may be in combination with additional therapeutic agents, including MDMA
40	39	Gosforth Centre (Holdings) Pty	US10028971B2	Compositions and methods for treating psychiatric disorders	2008-08-08	Granted 2018-07-24 (expires 2029-08-06)	Methods of treating mild cognitive impairment using an anti-epileptic agent and optionally one or more psychostimulants, the psychostimulants including MDMA
41	40	Univ. South Florida; US Dep't Veterans Affairs	US20190167653A1	Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with a-beta peptide aggregation	2008-06-30	Pending	Methods of treating a stress disorder or condition by using cotinine (a nicotine metabolite) together in some embodiments with MDMA; methods "can be used in combination with...various forms of psychotherapy"
42	41	Oron Zachar	US20110144209A1	Use of vasoconstrictors	2008-06-30	Abandoned	Methods of treating cancer by drug-induced hyperthermia caused by administering a vasoconstrictor, including MDMA
43	42	Daniel Schwartz	US20090264475A1	Methods and compositions for altering dietary behavior	2008-01-24	Abandoned	Methods of altering dietary behavior, by adding one or more positively-reinforcing compounds into healthy foods, the compounds including MDMA
44	43	Pisgah Labs	US10183001B1	Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features	2007-05-22	Granted 2019-01-22 (expires 2027-10-13)	Drug products with improved safety and anti-abuse properties, comprising a matrix of BNDO and an active compound, including MDMA
45	44	Pisgah Labs	US9421266B2	Safety of pseudoephedrine drug products	2007-05-22	Granted 2016-08-23 (expires 2027-10-05)	Drug products with improved safety and anti-abuse properties, by the inclusion of alditol acetals to reduce bioavailability in the mucosal membranes, the active compounds including MDMA
46	45	Pisgah Labs	US20080293695A1	Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance	2007-05-22	Abandoned	Drug products that can be administered therapeutically but having anti-abuse properties when used non-therapeutically, the active compounds including MDMA
47	46	Auspex Pharmaceuticals	US20080045588A1	Preparation and utility of substituted amphetamines	2006-08-02	Abandoned	Deuterated amphetamines including MDMA and MDA, processes of their preparation, pharmaceutical compositions thereof, and methods of their use for the treatment and/or management of trauma, e.g., PTSD
48	47	Duke University	US8877802B2	Antiparkinsonian action of phenylisopropylamines	2005-07-28	Granted 2014-11-04 (expires 2033-03-04)	Methods of treating Parkinson's disease comprising administering synergistic amounts of L-Dopa in combination with MDMA
49	48	Randal J. Kirk	US20090239783A1	Synergistic effects of combined administration of mirtazapine and a stimulant compound	2004-11-08	Abandoned	Compositions of a stimulant and mirtazapine, where the stimulant can include MDMA; methods of their use and manufacture
50	49	Shire	US20060100136A1	Synergistic effects of combined administration of mirtazapine and a stimulant compound	2004-11-08	Abandoned	Compositions of a stimulant and mirtazapine, where the stimulant can include MDMA; methods of their use and manufacture
51	50	Mayo Foundation, NIH, DHHS	US20080033029A1	Treating digestive tract conditions	2004-05-06	Abandoned	Methods for treating a digestive tract condition by administering a serotonin receptor agonist, including MDMA
52	51	Lohmann Therapie Systeme GmbH	US8980308B2	Transdermal pharmaceutical preparation containing active substance combinations, for treating Parkinson's disease	2003-08-20	Granted 2015-03-17 (expires 2029-07-04)	Transdermal pharmaceutical preparations for treating Parkinson's disease containing L-Dopa and other active agents including MDMA
53	52	Agouron Pharmaceuticals, Pfizer	US20040224960A1	Pharmaceutical compositions and methods for their use	2003-02-21	Abandoned	Methods of increasing the bioavailability of drugs by coadministration of a CYP450-inhibiting compound, the drugs including MDMA
54	53	Pfizer	US20020013372A1	Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors	2000-03-14	Abandoned	Methods of generating pharmacophore models for the CYP2D6 inhibitory potency of SSRIs for in silico drug screening, including by using MDMA in a training set of compounds
55	54	Pfizer	US20030144220A1	Use of CYP2D6 inhibitors in combination therapies	1999-04-07	Abandoned	Methods of administering drugs that are metabolized by CYP2D6 in combination with a CYP2D6 inhibitor, to improve the drugs' pharmacokinetic profile, the drugs including MDMA
56	55	University of Minnesota	US5028611A	Treatment for cocaine use	1989-06-29	Granted 1991-07-02 (expired 2009-06-29)	Method for reducing cravings and the use of psychostimulants and psychoactive compounds comprising orally administering carbamazepine, the compounds including MDMA
57	56	Yale University	US5059600A	Treating habit disorders	1989-03-31	Granted 1991-10-22 (expired 2009-03-31)	Methods of treating drug disorders comprising administering flupenthixol, the drug disorders including addiction to, abuse of, or dependency on MDMA
58	57	Thomas Hosick	US4120976A	Treatments for arthritis and cast dermatitis	1977-12-13	Granted 1978-10-17 (expired 1997-12-13)	Methods of relieving the symptoms of arthritis and cast dermatitis comprising administering MDA (note: not MDMA) in dosage amounts of approximately 0.2 to 1.5 mg/kg of body weight.
59	58	Merck	DE279194	Verfahren zur Darstellung von Hydrastinin Derivaten	1912-12-24	Granted 1914-10-15 (expired)	Method of coverting MDMA to methylhydrastinine, a methylated analogue of hydrastinine ("Process for the preparation of hydrastinine derivatives")
60	59	Merck	DE274350	Verfahren zur Darstellung von Alkyloxyaryl-, Dialkyloxyaryl- und Alkylendioxyarylaminopropanen bzw. deren am Stickstoff monoalkylierten Derivaten	1912-12-24	Granted 1914-05-16 (expired)	Method of synthesizing MDMA ("Process for the preparation of alkyloxyaryl, dialkyloxyaryl and alkylenedioxyarylaminopropanes and their derivatives monoalkylated on the nitrogen")